TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?
Brief Summary: In Sub-Saharan Africa (SSA), many children die from diarrhoea, acute respiratory illness (ARI) and malaria, despite well- recognized, inexpensive and highly effective treatments, since health access and human resources are limited. Healthy Child Uganda (HCU) is a Ugandan-Canadian partnership that since 2003, has developed, implemented and evaluated a Village Health Volunteer (VHV) program in 175 rural villages. Volunteers, selected by peers, provide health education and refer sick children. Volunteer retention (94%) and significant decreases in child deaths are remarkable. Now, HCU wonders whether VHV scope can extend to provide treatment for sick children using Oral Rehydration Salts (ORS)/Zinc, antibiotics, and antimalarials. Use of lay providers in this capacity, called integrated community case management (iCCM), has been proposed as a potential inexpensive solution to SSA's human health resource crisis.

PRIMARY QUESTION: In rural southwest Uganda, can iCCM provided by lay volunteers, improve the proportion of children with diarrhoea receiving ORS/Zn, ARI receiving antibiotics, and fever/malaria receiving antimalarials? Secondary study questions consider VHV capacity to prescribe appropriate drug, dose, duration; iCCM acceptance by family, and VHV; VHV retention/motivation; program cost. Selected VHV will be iCCM trained then receive treatments for distribution. Qualitative and quantitative methods including household surveys, and focus groups will consider pre/post intervention differences and differences in control and intervention populations. A research short course and micro research grants (\~ $3000 to multidisciplinary groups pursuing relevant questions) will promote health system evaluation capacity. Lessons learned are critical as SSA countries move forward in planning for increased iCCM programming.


Options:
A: Inclusion Criteria:

* Age between 6 months and 5 years
* Present with history of fever or reported fever
* Present with cough or difficult breathing

Exclusion Criteria:

* Age below 6 months and above 5 years
* Presence of signs and symptoms of severe illness
B: Inclusion Criteria:

* Children under five (\< or =59 months)

Exclusion Criteria:

* Children over five years (\> 59 Months)
C: Inclusion Criteria:

* All births

Exclusion Criteria:

* None
D: Inclusion Criteria:

* Participants who give consent to be treated at Health Post by Health extension worker

Exclusion Criteria:

* If Newborn is Critically sick

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?
Brief Summary: In Sub-Saharan Africa (SSA), many children die from diarrhoea, acute respiratory illness (ARI) and malaria, despite well- recognized, inexpensive and highly effective treatments, since health access and human resources are limited. Healthy Child Uganda (HCU) is a Ugandan-Canadian partnership that since 2003, has developed, implemented and evaluated a Village Health Volunteer (VHV) program in 175 rural villages. Volunteers, selected by peers, provide health education and refer sick children. Volunteer retention (94%) and significant decreases in child deaths are remarkable. Now, HCU wonders whether VHV scope can extend to provide treatment for sick children using Oral Rehydration Salts (ORS)/Zinc, antibiotics, and antimalarials. Use of lay providers in this capacity, called integrated community case management (iCCM), has been proposed as a potential inexpensive solution to SSA's human health resource crisis.

PRIMARY QUESTION: In rural southwest Uganda, can iCCM provided by lay volunteers, improve the proportion of children with diarrhoea receiving ORS/Zn, ARI receiving antibiotics, and fever/malaria receiving antimalarials? Secondary study questions consider VHV capacity to prescribe appropriate drug, dose, duration; iCCM acceptance by family, and VHV; VHV retention/motivation; program cost. Selected VHV will be iCCM trained then receive treatments for distribution. Qualitative and quantitative methods including household surveys, and focus groups will consider pre/post intervention differences and differences in control and intervention populations. A research short course and micro research grants (\~ $3000 to multidisciplinary groups pursuing relevant questions) will promote health system evaluation capacity. Lessons learned are critical as SSA countries move forward in planning for increased iCCM programming.


Options:
A: Inclusion Criteria:

* living in one of the study cluster (villages)
* no story of allergy to any of the study drugs
* history of fever or body temperature \>= 38.5°C

Exclusion Criteria:

* signs of severity/complications like impaired consciousness, convulsions, fast breathing etc
B: Inclusion Criteria:

* Children under five (\< or =59 months)

Exclusion Criteria:

* Children over five years (\> 59 Months)
C: Inclusion Criteria:

* Women living in intervention and comparison villages
* Mother to at least one child under 59 months old

Exclusion Criteria:

-No living child
D: Inclusion Criteria:

* Reproductive age women (aged 15-49 years)
* Permanently living in the study area
* No plans to leave the study area in the subsequent three years
* Written informed consent is obtained

Exclusion Criteria:

* Non-permanent community members (i.e. seasonal migrants)
* Plans to leave study area in the subsequent three years

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection
Brief Summary: The goal of this study is to gather input from patients who have undergone PCI, their family and/or caregivers, and clinicians to develop a patient decision aid. The purpose of the decision aid is to deliver information, including individualized estimates of patients' restenosis risk, in an understandable format that would be informative and assist in decision-making for patients undergoing PCI.


Options:
A: Inclusion Criteria:

* Asymptomatic average-risk subjects
* Under the direct care of one of participating site's staff (attending) physicians or physician extenders;
* No prior screening other than fecal occult blood testing (FOBT);
* No major co-morbidities that preclude CRC screening by any method

Exclusion Criteria:

* Prior CRC screening by any method other than FOBT occult blood testing
* High-risk condition (personal history of colorectal cancer or polyps, family history of colorectal cancer or polyps involving one or more first degree relatives, chronic inflammatory bowel disease)
* Lack of fluency in written and spoken English (since decision aid and personalized risk assessment tool will be in English only due to funding issues);
* Comorbidities that preclude CRC screening by any method
B: Inclusion Criteria:

* \>18 years old
* English or Spanish speaking
* Presence of coronary disease, or a caregiver/relative of one with coronary disease

Exclusion Criteria:

* non-English or non-Spanish speaking
* dementia
C: Inclusion Criteria:

* Utah resident
* Meets National Comprehensive Cancer Network (NCCN) guidelines for hereditary breast/ovarian cancer syndrome (personal and/or family history of breast and/or ovarian cancer, or is a member of a family with a known positive BRCA1/BRCA2 mutation).

Exclusion Criteria:

* Has had genetic counseling and/or BRCA 1/2 testing
* Physically or mentally unable to complete telephone surveys, telephone or in-person counseling or provide informed consent.
* Unable to read and speak English fluently
* Unable to travel to in-person genetic counseling session (17 in-person sites throughout Utah)
* Male gender
D: Inclusion Criteria:

* Patients showing new or recurrent symptoms of uterine fibroids (e.g. heavy menstrual bleeding, pelvic pressure or pain, etc.) who are seeking treatment.
* Assigned female sex at birth
* At least 18 years of age
* Speak English or Spanish
* Have the ability to complete short surveys online independently or assisted by a caregiver.

The investigators will also include health care professionals who will provide care to women with symptomatic uterine fibroids during the project duration at participating sites.

Exclusion Criteria:

* Patients who are under 18
* Patients not assigned female sex at birth
* Women who are postmenopausal because they will have different treatment options than the ones presented in this study's intervention.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians
Brief Summary: Musculoskeletal disorders and stress of employees remain a major problem in many occupations. The aim of this study is to investigate the effect of an individually tailored bio-psycho-social intervention strategy versus "usual care" ergonomics and standard physical exercises (reference group) on musculoskeletal pain, work disability, and stress in lab technicians with a history of work-related musculoskeletal pain.


Options:
A: Inclusion Criteria:

* We will recruit overweight/obese (body mass index 25.0-40.0 kg/m2) adults (18-65 years) working in full-time (minimum 35 hours/week), sedentary (self-report sitting \>75% work time) occupations at an independent work site.

Exclusion Criteria:

* Working in an office that will not meet the space or electrical requirements of the active workstation, acute or chronic illness not under treatment of a provider, orthopedic limitations that prohibit physical activity, current or planned pregnancy, hospitalization from a physical or mental disorder in the past six months and/or taking medication that may impair physical activity
B: Inclusion Criteria:

* Laboratory technician
* Pain intensity \>= 3 (scale of 0-10)
* Pain duration \>= 3 months
* Pain frequency \>= 3 days per week

Exclusion Criteria:

* life threatening disease
* pregnancy
C: Inclusion Criteria:

* All healthcare workers in the 4 hospital sites
* History of acute or subacute lower back pain in the 3 past years

Exclusion Criteria:

* History of surgery for spinal fractures
* History of lumbosacral arthrodesis
* History of surgical intervention or discal hernia, more than 2 levels or more than twice
* Radiculalgia with sign of motor deficit, or radiculalgia with a positive Lasègue sign
* Eligible for enrollement in a functional restoration program for lower back pain
* Ongoing low back pain (lumbago)
* Psychosocial or behavioural impairment
* Unstable cardiac disease
* Inability to fill out the questionnaires and scales (inability to understand French)
* Pregnancy
D: Inclusion Criteria:

* Office workers with mainly sedentary tasks
* BMI 25-40

Exclusion Criteria:

* Severe depression and/or anxiety
* Exhaustion disorder
* Diabetes Mellitus
* Severe cardiovascular disease
* Severe kidney disease
* Musculoskeletal disorders that prohibit walking on a treadmill
* Contraindications for physical activity
* Thyroidea illness
* Pregnancy

For fMRI-study, additional exclusion criteria are:

* Implanted metal- or electrical devices
* Pregnancy
* Extraneous metal pieces in the body

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial
Brief Summary: Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.


Options:
A: Inclusion Criteria:

Communities

* The community location in target district.
* The community leader consents to participation in the trial
* The community's estimated population is between 200-2,000 people.
* The community is not in an urban area.

Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census.

Exclusion Criteria:

Individuals

- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)
B: Inclusion Criteria:

* Must have been residing in the village for at least three months;
* Must be 90 cm tall or more;
* Must be between 5 years and 65 years of age;
* Must not be pregnant;
* Must not be lactating.

Exclusion Criteria:

* Subjects under 5 years of age or less than 90 cm in height;
* Subjects over 65 years of age;
* Subjects who cannot swallow tablets;
* Subjects who are sick and bedridden;
* Pregnant women (clinical appreciation in the study);
* Lactating women;
* History of allergies to the drugs being studied (azithromycin, ivermectin, albendazole).
C: Inclusion Criteria:

• All residents residing in the state-teams which are randomly selected for this study.

Exclusion Criteria:

* Pregnant women
* Children under 6 months of age
* All those who are allergic to macrolides or azalides
* Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

Individuals in these three exclusion criteria will not be given the study antibiotic azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day, topically to both eyes, for six weeks. Note that the exclusion criteria refer to the exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and examinations.
D: Inclusion Criteria:

Age 1 to 5 years old in a village in the Gurage zone with endemic trachoma

Exclusion Criteria:

Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial
Brief Summary: Our long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality. We propose a single multi-site (multi-country), cluster-randomized trial comparing communities randomized to oral azithromycin with those randomized to placebo. We hypothesize that mass azithromycin treatments will reduce childhood mortality.


Options:
A: Inclusion Criteria:

1. Diagnosis of chronic lung disease (defined as FEV1 and/or FVC \<80% predicted)
2. Age 6-19 years
3. Perinatally-acquired HIV infection the most likely source of transmission
4. On first or second-line ART for at least one year
5. HIV-1 viral load undetectable (as defined by each trial site)
6. A firm home address accessible for visiting and intending to remain there for 24 months
7. Willing to agree to participate in the study and to give samples of blood and sputum
8. HIV status disclosed to child for those aged older than 12 years

Exclusion Criteria:

1. Any condition (except HIV) that may prove fatal during the study period (e.g. malignancy, end-stage HIV disease or other conditions deemed likely fatal by the trial physician)
2. Diagnosis of active pulmonary TB
3. Infection with non-tuberculous mycobacteria (NTM)
4. Pregnant or breast-feeding
5. Condition likely to lead to lack of understanding of study procedures or to uncooperative behaviour e.g. neurocognitive disease, developmental delay or psychiatric illness
6. History of prolonged QTc syndrome or current or planned therapy with drugs likely to cause cardiac dysrhythmias
7. Abnormal ECG findings
8. Acute respiratory tract infection during enrolment (patients will be eligible once their acute infection is treated)
9. Creatinine clearance of \<30mls/minute
10. ALT more than 2 times the upper limit of normal
11. No defined guardian/stable caregiver
12. No consent/assent from guardian/child
B: Inclusion Criteria:

Communities

* The community location in target district.
* The community leader consents to participation in the trial
* The community's estimated population is between 200-2,000 people.
* The community is not in an urban area.

Individuals - All children aged 1-60 months (up to but not including the 5th birthday), as assessed via biannual census.

Exclusion Criteria:

Individuals

- Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)
C: Inclusion Criteria:

* Participation in the COPSAC2010 cohort
* recurrent wheeze
* and others

Exclusion Criteria:

* Macrolide allergy
* Heart, liver or kidney disease.
* and others
D: Inclusion Criteria:

* Age 1-59 months,
* Plan to remain in study area greater than 6 months
* Discharged from hospital following non-trauma related admission

Exclusion Criteria:

* Contraindication to azithromycin use and other prophylactic antibiotic use

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Early Childhood Obesity Prevention Program: Building Better Families and Communities
Brief Summary: This study is proposed on behalf of the Hartford Childhood Wellness Alliance, a 107 member, 35 group organization whose goal is to improve the health of children in Hartford, CT. In a randomized control trial, the primary aim of this study is to test the initial efficacy of a program of enhanced home visitation with neighborhood and community support to change maternal behaviors related to infant nutrition (sweetened beverage/juice consumption, breastfeeding and introduction of solids), parenting skills (establishing routines around sleep, reading cues for hunger, satiety, television time) and family wellness (improving the home food environment, enhancing physical activity). The investigators hypothesize that at 12 months of age, infants in the intervention arm will drink less sugar sweetened beverages/juices, will have ingested solids at an older age, will have been breastfed longer and more exclusively than infants in the control arm and will have less TV viewing, more established sleep routines and greater soothability (primary outcomes).


Options:
A: Inclusion Criteria:

* Parent of 8-12 year old child in 4-H Youth Development Programs in Montana
* Child of parent enrolled in study

Exclusion Criteria:

* Parent of child age outside the 8-12 year old range at start of trial
B: Inclusion Criteria:

* Enrolled in the Nurturing Families Network Program
* Singleton birth \>34 weeks gestation
* Any race or ethnicity
* ECHO neighborhood
* Mothers and their newborns

Exclusion Criteria:

* Mothers or newborns with special health care needs
* Infant with major malformation
* Small for Gestational Age/low birth weight
C: Inclusion Criteria:

* after-school program participant in fourth grade group
* informed parental consent
* assent to participate in Body Mass Index assessment

Exclusion Criteria:

* third or fourth grade student
* participant in study in previous year
D: Inclusion Criteria:

* all students enrolled in participating classrooms are invited to participate

Exclusion Criteria:

* none

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section
Brief Summary: The use of Oxytocin, Carbetocin and buccal misoprostol in patients undergoing elective Cesarean Section


Options:
A: Inclusion Criteria:

* At least one risk for postpartum hemorrhage and lack of hypersensitivity to oxytocin and carbetocin

Exclusion Criteria:

* Patients' refusal to cooperate, major therapeutic side effects, history of cardiac and renal disease or preeclampsia
B: Inclusion Criteria:

* home delivery
* presence of Community Health Officer at time of delivery

Exclusion Criteria:

* None
C: Inclusion Criteria:

1. Age 18 years or more.
2. Gestational age of pregnancy of 37 completed weeks or more.
3. Written and signed informed consent by the patient to participate in the study.

Exclusion Criteria:

1. fetal or maternal distress where, due to time constraints, it will not possible and/or appropriate to recruit or randomize.
2. Women undergoing caesarean section with general anesthesia are also excluded, because carbetocin is licensed for use with regional anaesthesia only.
3. Women planned to have any other type of uterine incision other than transverse lower segment.
4. Women with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), eclampsia, and epilepsy .
5. Women with placental abruption are excluded because there is a higher risk of hemorrhage with this condition and it was therefore felt to be inappropriate to recruit these women.
6. Women with thrombocytopenia, known coagulopathies, or receiving anticoagulant therapy.
7. Women with history of significant heart disease, a history or evidence of liver, renal, vascular disease or endocrine disease (other than gestational diabetes).
8. Women with history of hypersensitivity to oxytocin or carbetocin.
9. Women with any severe allergic condition or severe asthma.
10. Women with any contraindication to receiving prostaglandins, including known hypersensitivity to misoprostol or other prostaglandins (PGs) or glaucoma.
11. Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.
D: Inclusion Criteria:

* Vaginal delivery
* Postpartum hemorrhage due to suspected uterine atony
* Depending on study group: administration of prophylactic uterotonics in third stage of labor

Exclusion Criteria:

* Known allergy to misoprostol or other prostaglandin
* C-section for current delivery

Answer: C